

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/20050 A2

(51) International Patent Classification⁷: A61K 39/12

N.W. Bluff Drive, Parkville, MO 64152 (US). BROWN, Karen, K. [US/US]; 5501 N.W. Foxhill Road, Parkville, MO 64152 (US).

(21) International Application Number: PCT/US01/27600

(22) International Filing Date:
6 September 2001 (06.09.2001)

(74) Agent: BLACKSTONE, William, M.; 1300 Piccard Drive Suite 206, Rockville, MD 20850 (US).

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
09/659,026 9 September 2000 (09.09.2000) US

(71) Applicant (*for all designated States except US*): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, P.O. Box 186, NL-6800 LS Arnhem (NL).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MONTELARO, Ronald, C. [US/US]; 127 Greenbriar Drive, Wexford, PA 15090 (US). CRAIGO, Jodi [US/US]; 12 Hillcrest Drive, Pittsburgh, PA 15202 (US). ISSEL, Charles [US/US]; 725 Edgewater Drive, Lexington, KY 40502 (US). PUFFER, Bridget [US/US]; 219 Strathmore Place, Corning, NY 14830 (US). HENNESSEY, Kristina, J. [US/US]; 5215


Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: EIAV P26 DELETION VACCINE AND DIAGNOSTIC

Schematic representation of EIA virus EIAV_{UK}



(57) Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease with converting to a seropositive status on the Coggin's Test or any other test which measures p26, said p26 antigen being expressed in disease-producing wild-type EIAVs. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines. Finally, this invention encompasses a marker vaccine in which vaccinated equines can be distinguished from non-vaccinated equines by detection of a foreign gene in the vaccinated animals. A diagnostic test to detect this foreign gene or gene product is also described.

WO 02/20050 A2



— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

EIAV P26 DELETION VACCINE AND DIAGNOSTIC

BACKGROUND OF THE INVENTION

Field of the Invention:

This invention pertains to a vaccine composition which provides immunity from clinical disease signs and/or infections caused by lentiviruses including but not limited to Equine Infectious Anemia Virus (EIAV), Human Immunodeficiency Virus (HIV), Feline Immunodeficiency Virus (FIV), Bovine Immunodeficiency (BIV) and Simian Immunodeficiency Virus (SIV) or any other similar lentivirus. More specifically, but without limitation hereto, the invention relates to an Equine Infectious Anemia Virus (EIAV) composition which provides immunity from clinical disease signs and/or infection with EIAV, and which composition allows diagnostic differentiation between vaccinated and non-vaccinated but exposed or diseased mammals, and which allows the vaccinated animal to test negative using a Coggins test or other similar test that detects p26-specific antibodies

Brief Description of the Prior Art:

Lentiviruses are a subfamily of retroviruses that cause persistent infection and chronic disease in numerous types of mammals including humans (HIV), equines (EIA), felines (FIV), bovines (BIV) and monkeys (SIV). All of the diseases are spread by blood transmission. EIAV causes persistent infection and chronic disease in horses world wide. With EIAV, the blood transmission occurs by biting flies and other insects carrying virus particles from one horse to another. The first cycle of disease (clinical episode) in an infected horse usually occurs within 42 days after exposure to the virus. This first cycle is usually referred to as the acute stage of EIA and is characterized by pyrexia, thrombocytopenia, anorexia, depression and high plasma viremia levels. Anemia is not usually detected at this stage. Resolution of this first febrile episode is normally observed after 1 to 5 days and occurs concomitantly with a dramatic drop

in the amount of plasma-associated virus. Following the acute stage, some animals may remain clinically normal while others go on to experience multiple bouts of illness in which severe anemia may accompany pyrexia, thrombocytopenia, edema, and dramatic weight loss, and death. In instances of persistent infection by a lentivirus, as illustrated by EIAV, nucleotide sequence data has revealed a high mutation rate of the lentivirus genome as reported by Payne et al, Virology, 1987: 161, p. 321-331 which is incorporated herein by reference. With EIAV infections, it is generally thought that neutralizing antibodies aid in the selection of new antigenic virus variants during persistent infections. Also, with EIAV infections, serologically distinct variants of EIAV emerge possibly through immune selection pressure operating on random viral genome mutations. Without being bound to any particular theory, it is believed that horses that show no further clinical signs of disease have developed a mature immune response that can protect against the virus and its known mutations.

As a member of the lentivirus subfamily of retroviruses, EIAV is useful as a model for the pathogenicity, immunology, vaccinology, treatment and prevention of HIV. The disease is significant in its own right because horses that demonstrate exposure to EIAV as measured by testing for antibodies in the blood (Coggins Test or similar p26 detecting test) are either required to be destroyed or strictly quarantined. As a result of the Coggins Test requirement and its broad use throughout the world, especially in testing performance horses that are transferred into and out of the United States, it is critical that any effective EIA vaccine not be able to seroconvert horses to a positive Coggins Test or to any other test that detects p26. Therefore, for vaccines useful in protecting against EIA, it is important to either delete all or part of the gene expressing p26 or block its expression by deleting regulator genes or inserting stop codons or foreign genes. It is expected that use of the methods described herein can provide vaccines for the other lentiviruses (HIV, FIV, BIV and SIV) that can

elicit immune responses that are effective and that can be distinguished from viral infections.

- As with other lentiviruses such as HIV, BIV, FIV and SIV, the genetic organization of EIAV classifies it as a complex retrovirus. The
- 5 EIAV genome contains the canonical *gag*, *pol*, and *env* genes common to all retroviruses, and three accessory genes (*S1*, *S2* and *S3*). The *gag* gene encodes the core proteins of the virus designated as Matrix Antigen (MA), Capsid Antigen (CA), Nucleocapsid (NC) and a protein designated p9. The *env* gene encodes the viral envelope proteins (gp90 and gp45).
- 10 The *pol* gene encodes the enzymes that replicate the viral genome, designated as Deoxy UTPase (DU), Reverse Transcriptase (RT) and Integrase (IN). The *S1* open reading frame (ORF) encodes the viral Tat protein, a transcription *trans* activator that acts on the viral long-terminal repeat (LTR) promoter element to stimulate expression of all viral genes.
- 15 The *S3* ORF encodes the Rev protein, a post-transcriptional activator that acts by interacting with its target RNA sequence, named the Rev-responsive element (RRE), to regulate viral structural gene expression. The *S2* gene is located in the *pol-env* intergenic region immediately following the second exon of Tat and overlapping the amino terminus of
- 20 the Env protein (see Figure 1). It encodes a 65 amino acid protein with a calculated molecular mass of 7.2 kDa. *S2* appears to be synthesized in the late phase of the viral replication cycle by ribosomal leaky scanning of a tricistronic mRNA encoding Tat, *S2* protein, and Env protein, respectively.
- 25 The *gag*-encoded Capsid Antigen (CA) or p26 protein comprises the capsid shell of the virion that is enclosed in the viral envelope and that contains the viral RNA genome. Homologous CA proteins are present in HIV, FIV, BIV and SIV and are also encoded by the respective *gag* genes. As noted above, detection of antibodies to the p26 antigen is the basis for
- 30 the Coggins Test and certain other commercial tests used to diagnose EIA in horses. To be compatible with current regulatory guidelines, it is critical that any EIAV vaccine not stimulate seroconversion in these diagnostic

assays based on detection of serum antibodies to EIAV p26. The p26 antigen is highly antigenic in that extremely small amounts of its presence in a vaccine can stimulate antibody responses and seroconversion in diagnostic assays. Attempts to extract or delete p26 antigen from a pool of EIAV have not been practical for vaccine production. Therefore, it would seem that one could eliminate it by deletion of the *gag* gene, a segment of the *gag* gene that interferes with the expression of p26 or deletion or inactivation of a control gene that regulates the expression of p26. However, it has been determined by the inventors that deletion of the *gag* gene or segments thereof produces an EIAV particle that is unable to replicate *in vitro* (tissue culture) or *in vivo*. Therefore, simply deleting or blocking expression of p26 makes growth of EIAV for vaccine production impractical if not impossible.

To provide protection from disease and protection from infection, envelope proteins (Env) are considered the proteins of choice, as these proteins are the predominant immune targets during infection. By protection from disease is meant that a mammal exposed to the virus does not demonstrate clinical signs (fever, lethargy, anemia, death, etc.), but does carry virus particles in its blood, which particles are detectable by a reverse transcriptase polymerase chain reaction test (RT-PCR). By protection from infection is meant that a mammal exposed to the virus does not demonstrate clinical signs of EIA and does not contain RT-PCR-detectable virus particles in blood. The major envelope proteins of EIAV are gp90 and gp45. These are proposed as the protective antigens or protective components of EIAV. By the term protective components is meant antigens from that produce either protection from disease or protection from infection as indicated above. It is therefore important that any effective lentivirus vaccine contain amounts of the lentiviral Env proteins (such as gp 120, gp90 or gp45) effective to protect mammals from disease caused by the lentivirus. The protective components from EIAV include but are not limited to gp90 and gp45. The Capsid Antigen (p26) is not a protective component of EIAV and, because of its ability to

stimulate a significant antibody response, the vaccine of the present invention preferably lacks the ability to stimulate p26 antibodies in an equid.

It would seem obvious to prepare a vaccine by purifying out the Env proteins, especially gp90 and gp45 for EIAV. Indeed, vaccines comprising preparation from which gp90 and gp45 have been purified out of the EIAV have been attempted with extremely limited success. Issel et al (J. Virol. June 1992, p 3398-3408) reports that a gp90/gp45 vaccine protected ponies from infection caused by homologous EIAV (the subunits were derived from the same EIAV strain as was used for challenge). However, these subunit-containing vaccines did not protect horses from either disease or infection when challenged with a heterologous EIAV strain. In fact, the latter produced enhanced disease signs. The enhancement of disease by the subunit EIAV vaccine corroborates findings with SIV and FIV subunit vaccines that appear to enhance disease post challenge. Issel et al (ibid) concludes that perfecting a subunit vaccine for lentiviruses (e.g., HIV, FIV, EIA, BIV and SIV) poses a significant challenge because of the subunit enhancement effect.

Issel, et al (ibid) also reports the prevention of infection by a whole-virus EIAV vaccine. However, vaccination of horses with this vaccine produces horses that are Coggins Test positive (p26 positive). As mentioned previously, due to the eradication program in effect in the U.S., horses testing positive for p26 are either euthanized or strictly quarantined. Additionally, the amount of virus included in said vaccine was 1 milligram, an amount not commercially feasible. Therefore, this whole-virus vaccine is not compatible with regulatory requirements or commercialization.

A donkey virus vaccine has been in use by the Chinese for more than 20 years. This vaccine was developed by using total EIAV genetic material from donkey leukocyte attenuated EIAV infected cells and ribonucleic acid from virus in peripheral blood of donkey-adapted EIAV from infected donkeys (see Xinhua News Agency, May 6, 1999). As

would be expected, this vaccine produces a p26 positive response (Coggin's Test positive) in vaccinated horses or other vaccinated equids. Such a vaccine is not acceptable in those countries where equids are tested by Coggins assays or other p26-specific antibody tests. In addition, numerous countries will not accept live vaccines for veterinary applications.

Since there has been no effective and safe method for immunizing mammals against disease or infection caused by lentiviruses, particularly equines against EIA, and since lentivirus diseases, especially HIV, FIV and EIA are such a wide-spread and significant diseases world-wide, there remains a long-felt need to prepare such a vaccine.

The vaccine of this invention provides a successful vaccine composition that effectively and safely immunizes mammals from diseases caused by lentiviruses. The vaccine of the present invention protects equines from EIA wherein vaccinated equines can be differentiated from wild-type infected equines, which does not convert said equines to Coggins Test positive and which does not replicate *in vivo*. It is fully envisioned that the vaccines taught by the present invention can be used for production of any lentivirus vaccines, including vaccines for HIV, FIV, BIV and SIV.

DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of EIAV designated EIAV_{UK}

Figure 2 is a circular map of infectious clone EIAV_{UK}

Figure 3a is a linear schematic of the molecular clone EIAV_{UK}

Figure 3b is a linear schematic of molecular clone EIAV_{UK} with the CMV promoter.

Figure 3c is a linear schematic of molecular clone pCMVEIAV_{UK} with the CA gene deleted.

Figure 3d is a linear schematic of molecular clone pCMVEIAV_{UK}ΔCA with the Amp Resistance gene replaced by the Kanamycin Resistance gene.

Figure 3e is a linear schematic of the p26-deleted Proviral Clone pCMV. Δ CA.neo.

Figure 4 is a circular map of the p26-deleted Proviral Clone pCMV. Δ CA.neo.

5 Figure 5a is a linear schematic of the EIAV_{UK} molecular clone.

Figure 5b is a linear schematic representation of the EIAV_{UK} clone with the CMV promoter insert (CMVEIAV_{UK}).

Figure 5c is a linear schematic representation of the pCMVEIAV_{UK}.vis2.

10 Figure 5d is a linear schematic representation of the Proviral Clone containing the Kanamycin Resistance Marker.

Figure 5e is a linear schematic representation of the final pCMVEIAV_{UK}.Vis2.neo Proviral Construct.

15 Figure 6 is a Circular map of the final pCMVEIAV_{UK}.Vis2.neo Proviral Construct.

Figure 7 is the nucleotide and amino acid map of the CA gene/EIAV p26.

Figure 8 is the nucleotide and amino acid map of the CA gene/Visna p30.

20 Figure 9 is a comparison of the homology between p26 of EIAV and p30 of Visna virus.

Figure 10a is a Western Blot of p26-deleted clones, Visna chimeric clones & subclones of EIAV using gp90 & p26 monoclonal antibodies as the detector.

25 Figure 10b is a Western Blot of several p26-deleted clones, Visna chimeric clones & subclones of EIAV using p30 monoclonal antibody as the detector.

Figure 11 is a graph demonstrating the Reverse Transcriptase Activity of various subclones of ED cells transfected with
30 pCMVEIAVUK.Vis2neo Proviral Construct.

SUMMARY OF THE INVENTION

This invention encompasses a safe and effective vaccine that produces immunity to mammals from infection and/or disease caused by a lentivirus. Examples of the lentivirus can be equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said vaccine comprising a deletion in the gene encoding the Capsid Antigen. More specifically, the invention encompasses a vaccine comprising a deletion that produces a lack of ability of the lentivirus to express the Capsid Antigen and to replicate *in vivo* while retaining the lentivirus protective components. Also, the vaccine allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. By the term safe is meant that vaccination with of mammals with vaccines of the present invention does not produce infection, disease or any other adverse reaction in the vaccinated mammals. Said vaccine encompasses at least one deletion in a lentivirus, which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. The invention further encompasses a lentivirus with a deletion in the *gag* gene, specifically a deletion that results in an inability of the lentivirus to express the Capsid Antigen (CA protein) *in vivo* or *in vitro*. Finally, the EIAV vaccine of the present invention lacks the ability to stimulate p26 antibodies in an equid.

In a preferred embodiment, the invention encompasses a vaccine for effectively and safely immunizing mammals from EIA, said composition comprising a gene-deleted EIAV construct wherein said gene-deleted construct interrupts virus replication *in vivo* and blocks the expression of p26 *in vivo* while retaining the EIAV protective components. As such, vaccinated equines would be protected from disease caused by EIAV and not convert to a seropositive status on the Coggins Test or any other test that measures p26 antibodies. As used herein, the term EIA refers to the disease Equine Infectious Anemia and the term EIAV refers to the Equine

Infectious Anemia Virus that causes the disease. Additionally, said EIAV vaccine cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

A more specific embodiment of the invention is a vaccine wherein
5 the lack of ability to express p26 antigen results from one or more gene deletions within the *gag* gene, one or more deletions within a gene having a regulatory effect on *gag* CA production, an insertion of one or more stop codons into the *gag* CA gene or a gene regulating CA production, or insertion of a foreign gene into the *gag* CA gene or a gene regulating CA
10 production. By insertion of a foreign gene is meant that the gene being inserted is not a gene associated with EIAV. Said foreign gene is obtained from a non-EIAV organism.

Additionally, it is expected that further deletions could be made such that the EIAV in the vaccine contained multiple deletions including
15 but not limited to a deletion in the *gag* gene affecting the expression of p26.

Finally, it is expected that said gene deletions (deleted regions) could serve as potential points for insertion of foreign genes to produce a multiple-protective vaccine. This means that a single vaccination with the
20 EIAV vaccine carrying a foreign gene (e.g., influenza hemagglutinin (HA) gene) could protect the mammal from both the lentivirus disease (e.g., HIV or EIA) and the disease associated with the foreign gene insert (e.g., human or equine influenza).

DETAILED DESCRIPTION OF THE INVENTION

25 This invention provides a vaccine for effectively and safely immunizing mammals against diseases caused by lentiviruses selected from the group consisting of EIAV, HIV, FIV, BIV and SIV, said vaccine comprising a gene-deleted lentivirus construct. The invention encompasses a vaccine comprising a deletion that produces a lack of
30 ability of the lentivirus to replicate *in vivo* and retains the lentivirus protective components. By lentivirus protective components is meant the protective antigens associated with the envelope of the lentiviruses

including but not limited to gp120, gp90 and gp45. The invention encompasses a lentivirus that is unable to express the Capsid Antigen (CA protein) *in vivo*.

5 A deletion can be produced in the lentivirus genome by using specific restriction endonucleases to remove all or part of one or more genes. A preferred gene for removal is the gene encoding the Capsid Antigen (CA). Such gene deletion can be accomplished by using PCR, ligation and PCR cloning; to delete the selected gene sequence. Restriction endonucleases can also be used to remove specific portions of
10 genes once the gene sequence of the lentivirus and the gene sequence of the gene to be excised are known. Using specific restriction endonucleases, the *gag* gene can be removed in whole or part. Additionally, a stop codon can be inserted into the gene, preferably at the 5' end wherein the stop codon causes the gene not to express its CA
15 protein. Additionally, a foreign gene from another lentivirus or an unrelated virus can be inserted into the gene-deleted region producing a multiply protective vaccine. In the latter case, the invention describes the deletion of a region of the EIAV genome large enough to insert a gene expressing a protective antigen from a non-EIAV organism, preferably a
20 virus. Therefore, the HA gene from equine influenza A2 or A1 can be inserted into the *gag* CA region allowing expression of gp90 and gp45 of EIAV as well as HA of A1 and A2 equine influenza. This will provide a vaccine that can protect from disease in equines caused by EIAV and equine influenza viruses. Also, genes from equine herpes viruses types 1,
25 2, and 4 can be inserted into the EIAV construct to provide protection against disease of equines caused by EIAV and equine herpes viruses. Other equine viruses which could have genes encoding for protective antigens inserted in the EIAV include but are not limited to equine arteritis, encephalomyelitis viruses (Eastern, Western, Venezuelan and Rift Valley
30 Fever virus). Genes encoding protective antigens from parasites (*Sarcocystis neurona* that causes Equine Protozoal Encephalitis or EPM, *Neospora heugesi* that is also possibly related to EPM, *Toxoplasma*

gondii, etc.) can also be inserted into an EIAV construct to protect against these diseases. Finally, genes encoding for bacterial diseases of horses, including but not limited to *Streptococcus equi* and *Clostridium tetani*, can be inserted into an EIAV construct to provide multiple disease protection.

- 5 It is expected that even a gene encoding for an immunostimulatory protein (immunomodulator gene) or glycoprotein can be inserted into the gene-deleted region in order to enhance the immunity provided by the virus construct.

Broadly described, a method for deleting a gene of a lentivirus (eg
10 the CA gene) and insertion of a foreign gene utilizes the techniques of PCR, ligation, and a method of PCR cloning.

Primers are designed to amplify a region of a promoter-lentivirus genome upstream of the CA open reading frame (ORF). Additional primers are used to amplify the region of the promoter-lentivirus genome
15 downstream of the CA. The amplified PCR products are purified using agarose gel electrophoresis and ligated together. A final round of PCR is performed using the 5' primer of the upstream fragment, and the 3' primer of the downstream fragment, followed by gel purification. The final product would comprise a representative size of the *gag* gene with a
20 deletion of the CA open reading frame. The PCR product is gel purified and digested with specified restriction endonucleases such that it can be ligated with a plasmid that had been digested with the same restriction enzymes or enzymes producing the same blunt ends. The ligated insert is preferably added to a lentivirus clone comprising a promoter and genes
25 allowing for selection of clones (e.g., antibiotic resistance genes) thus producing a promoter-lentivirus clone. Then the promoter-lentivirus clone is transformed into competent bacterial cells and colonies of the bacteria are screened for insertion of the genes. Clones may be genetically sequenced to verify that the CA region had been deleted and an insert
30 had been made.

A gene-deleted construct could be commercially produced (produced in large scale) by transfecting susceptible tissue culture cells,

harvesting the fluids and formulating the fluids with an adjuvant.

Optionally, the harvest fluids may be inactivated with art-known inactivating agents such as formalin, binary ethyleneimine, beta-propiolactone, thimerasol and psoralen. By gene-deleted construct is

- 5 meant a lentivirus in which a gene is non-functional due to a deletion, an insertion of a stop codon, or production of a gene insertion in which the deleted gene is replaced by a gene from another virus.

- If said gene-deleted lentivirus cannot replicate *in vitro*, tissue culture cells may be transfected with the construct using transfecting
- 10 agents such as DEAE dextran, GenePORTER™ (Gene Therapy Systems), etc., to incorporate the necessary genomic material into the cell DNA such that the cells produce lentivirus antigens. For transfection, tissue culture cells are seeded into wells of tissue culture vessels (eg plates), exposed to the gene-deleted construct or the gene-deleted/gene-
- 15 inserted construct in the presence of a transfecting agent, incubated to allow transfection and then overlaid with a selection medium. Selection media is defined as any nutrient medium that contains components to kill non-transfected cells but does not inhibit growth of transfected cells. To accomplish this, generally, gene-deleted constructs contain inserts of a
- 20 resistance gene in order to allow the construct to grow in said selection media. Selection media can contain antibiotics, antimicrobials and selective antibiotics. Once transfected cells have been selected and are replicating they are tested for production of protective antigens as well as for the absence of expression of the deleted gene product. Those clones
- 25 demonstrating these characteristics are then expanded in selection media by removing the cells from their initial container, diluting them and replanting them into larger containers. For instance, initial transfection may be carried out in 24 well tissue culture plates. After selection of clones, the surviving transfected cells are passaged to 6 well plates, 25
- 30 cm² flasks, 75 cm² flasks and then to roller bottles (1700cm² or larger). Transfected cells should consistently produce the virus construct, indicating a stable transfected or producer cell. After the transfected cell

clones have been demonstrated to be stable, stable-transfected Master Cells (also referred to as persistently infected cells by various regulatory agencies) can be prepared for expansion into Working Cells and Production Cells. Working Cells are defined as those cells that are used
5 to prepare Production Cells. Production Cells are the cells used to manufacture vaccines. Master Cells, Working Cells and Production Cells are all generally stored in liquid nitrogen for retaining viability and stability of the transfecting clone.

In the practice of this invention, a vaccine comprising a gene-
10 deleted construct lacks the ability to replicate *in vivo* and, possibly, *in vitro*. As should be realized by the foregoing, this type of deletion, if producing an inability to replicate or grow *in vitro*, requires transfection and cloning, as described above.

The following is an illustrative but non-limiting description of a
15 lentivirus that is unable to express the Capsid Antigen protein (CA or p26) *in vivo*. It has been determined that with EIAV, a deletion in the CA such that the p26 is not expressed results in a gene-deleted construct that cannot replicate *in vitro* or *in vivo*. For this reason, it is expected that such a CA deleted lentivirus would have to be produced in a stable transfected
20 cell line. This means that it would have to be transfected as described above in order to produce the stable transfected cell line.

This invention more specifically encompasses a vaccine wherein the lack of ability to express p26 antigen is produced by one or more gene deletions within the *gag* gene or one or more deletions within a gene
25 having a regulatory effect on *gag* CA production, or an insertion of one or more stop codons or insertion of a foreign gene.

It is expected that further deletions could be made such that the EIAV in the vaccine composition contained multiple deletions including but not limited to a deletion in the *gag* gene affecting the expression of p26.
30 Finally, it is expected that said gene deletions (deleted regions) could served as potential points for insertion of foreign genes to produce a multiply-protective vaccine and a very important feature for EIAV, a marker

vaccine. A marker vaccine is a vaccine that contains a foreign gene that produces antibody in the mammal receiving a vaccination, said antibody being detected by a diagnostic test and being used to distinguish a vaccinated equid from a non-vaccinated equid and a vaccinated equid from an infected equid. With EIAV, it is preferred to insert a CA gene from a different lentivirus that does not cross-react with p26 in the Coggins Test or equivalent tests. Therefore, insertion of the p30 gene from a different lentivirus such as a Visna virus would be expected to allow an EIAV vaccine to be used for vaccination of mammals, preferably equids. Said equids would demonstrate no p26 antibody in the Coggins Test or any other test measuring the presence of antibody to p26 antibodies, and would, additionally, demonstrate antibody to p30 which could be detected by an enzyme linked immunosorbant assay (ELISA), immunodiffusion test, fluorescent antibody test (FA), or any other test that can be used to detect antibodies in mammals.

It is expected that the gag gene-deleted constructs discussed above will not grow or replicate *in vitro*. Therefore, in order to produce large quantities for manufacturing purposes, the cloned constructs can either be expressed by bacterial cells or by mammalian cells (tissue culture). The process of transformation has been described briefly above and is described in detail in the EXAMPLES. Production of a stable transfected tissue culture cell line (persistently infected Master Cell) is preferable and is accomplished by transfecting mammalian cells in tissue culture. A preferred technique for EIAV constructs is described in the examples to follow.

The resulting p26 deleted construct can be employed in a vaccine for effectively and safely immunizing equines from EIAV, said vaccine comprising a gene-deleted EIAV construct wherein said gene deletion blocks the expression of p26 *in vivo*.

Vaccine viruses or virus constructs of this invention can be further treated with inactivating agents such as formalin, beta propiolactone, binary ethyleneimine, thimerasol or any other that effectively inactivates

viruses. Such agents can be used in amounts varying from 0.00001% to 0.5%, preferably from 0.00001% to 0.1% and more preferably from 0.00001% to 0.01%.

Additionally, adjuvants or immunomodulators/immunostimulators
5 may be added to the vaccine to enhance the immune response produced by the vaccine. Adjuvants can be selected for the group consisting of polymers such as Carbopol®-based, HAVLOGEN® and POLYGEN®, block co-polymers, oil-in-water such as EMULSIGEN® or EMULSIGEN® PLUS, water-in-oil, aluminum salts, lipid-based, lipoprotein, endotoxin-
10 based and combinations thereof. Immunomodulators and immunostimulators include but are not limited to *Corynebacteria pyogenes* and extracts or subunits thereof, parapox viruses and extracts or subunits thereof, modified live viruses that stimulate interferon production, as well as cytokines.

15 The vaccines of this invention can be administered by any route. For instance, they can be administered intramuscularly, subcutaneously, intradermally, intranasally, orally, intravenously or intraperitoneally. It is preferable to administer the vaccines either intramuscularly, subcutaneously, orally or intranasally.

20 Other antigens may be added to the vaccines such that a multi-component vaccine can be produced. In order to accomplish this, antigens from other viruses, bacteria or parasites are formulated with adjuvants or other excipients and then combined with the EIAV construct of this invention. Therefore, this invention encompasses an EIAV
25 construct combined with antigens from the group selected from equine influenza (A1 and A2), equine herpes virus (subtypes 1, 2, 3 or 4), equine arteritis virus, eastern equine encephalomyelitis, western equine encephalomyelitis, Venezuelan equine encephalitis, Rift Valley Fever Virus, *Sarcocystis neurona*, *Neospora hughesi*, *Toxoplasma gondii*, *Giardia lamblia*, *Streptococcus equi*, *Streptococcus zooepidemicus*, *Rhodococcus equi*, *Clostridium botulinum*, *Clostridium tetani*, *Clostridium difficile* or any
30

other equine disease-producing agent. The *Clostridium botulinum* can include types A, B, C, D, E, and/or F.

Finally, it is within the scope of this invention that a diagnostic test can be used to differentiate vaccinated equines from non-vaccinated
5 and/or infected equines by measuring the presence or absence of antibodies to the deleted gene protein. Also, a PCR-based diagnostic test could be used to detect the presence or absence of the genes or gene sequences in body fluids or tissues from the equine and, thus, detect whether an equine had been infected with EIAV or vaccinated with the
10 composition of this invention. The diagnostics of choice measure the presence or absence of p26 antibodies in an equine. Additionally, if an inserted gene is from a non-equine organism such as a Visna virus, a protein product of the non equine organism could be measured. An example described herein includes the insertion of the p30 gene from
15 Visna virus wherein the p30 can be detected in vaccinated equines but is not present in non-vaccinated or EIAV infected equines.

Diagnostic differentiation can be measured by developing an immunoassay, an antibody-detecting assay (e.g., indirect fluorescent antibody, immunodiffusion, agar diffusion, electrophoresis) or a PCR-
20 based assay known to the art. An example of an immunoassay is an enzyme linked immunosorbant assay (ELISA) that detects and/or quantitates antibodies to specific proteins in serum, blood or tissues. ELISA technology could also be used to detect the presence or absence of virus-associated antigens in the blood, serum or tissues. By virus-
25 associated antigens is meant the presence or absence of a gene expression product such as the p26 protein of EIAV or p30 protein of Visna virus or in the case of the p26 or p30 genes, respectively. PCR-based assays have been used to measure the presence or absence of genes or gene sequences in the blood, serum or tissues of an equine,
30 thus indicating that a horse had been infected or vaccinated, as the case may be. For this particular embodiment, an ELISA would detect the presence of antibodies to the p26 or p30 proteins. If p26 antibodies were

present in horses that were tested it would indicate that the horse had been infected with EIAV. Horses that had been vaccinated with a gene-mutated EIAV construct containing a non-functional p26 gene would not contain p26 antibodies in their serum. Horses that had been vaccinated
5 with a gene-mutated EIAV construct containing a p30 gene insertion would contain p30 antibodies in their serum. Thus, vaccinated horses could be differentiated from infected horses. The PCR-based assays would be used to detect the presence or absence of gene sequences within the horse. For instance, if a horse had been infected with a wild-
10 type EIAV, it would contain the gene sequence for wild-type p26. However, equines immunized with vaccines comprising a gene-mutated EIAV, particularly one wherein the p26 gene comprised deletions or specific mutations would not contain the gene sequence for wild-type p26. Alternatively, horses that had been vaccinated with a gene deleted EIAV
15 construct containing a p30 gene insertion would contain the p30 gene sequence in their serum.

These and other aspects of the invention are further illustrated by the following non-limiting examples. In the examples and throughout the specification, parts are by weight unless otherwise indicated.

20

EXAMPLE 1

Construction of the p26 Deletion Mutant Proviral Clone designated as pCMV. Δ CA.neo: In order to determine whether deletion of all or part of the CA gene was possible, it was decided to delete the entire p26 gene
25 from EIAV. The molecular clone EIAV_{UK} as described by Cook et al. Journal of Virology 72(2): 1383-1393, 1998 which is incorporated herein by reference, was used for derivation of the proviral clone. Figure 2 displays a circular map of the EIAV_{UK} molecular clone. Figure 3a displays a linear schematic in order to demonstrate the methods used for the
30 constructs described in this example. Figure 6 shows the specific sequence of the CA gene and the amino acid sequence of p26 of the EIA virus that it encodes.

The procedure for the construction of the p26 deletion mutant proviral clone (pCMV. ΔCA.neo) was as follows. First, the CMV promoter was inserted into the 5' LTR region through a process of PCR, ligation, and PCR cloning. Primers CMV3'Blunt (SEQ ID No. 1) and 5'CMVBssH (SEQ ID No. 2) were used to amplify the CMV promoter from the plasmid pRC/CMV (InVitrogen). PCR conditions were set up as follows in thin-walled 0.5ml PCR tubes (PGC Scientific): 40.6μl dH₂O, 5μl cloned Pfu DNA Polymerase 10X reaction buffer, 0.8μl 25mM Deoxy- A,C,G,T (nucleotide) tri-phosphate (dNTP) mixture, 2.5μl each primer (100ng/μl), 1μl template DNA (10ng/μl) 2.0μl cloned Pfu DNA Polymerase (2.5U/μl-Stratagene). Amplification was performed in a Hybaid thermocycler and consisted of 30 cycles of: 94°C-20seconds, 60°C-20 seconds, 72°C-1 minute. Primers LTRBlunt5' (SEQ ID No. 3) and MA3'Tth (SEQ ID No. 4) were used to amplify a region of the EIAV_{UK} clone encompassing the portion of the genome including the final 31 base pairs of the terminal redundancy region (R region) through the MA open reading frame in similar reaction conditions. The two PCR products (50μl) were gel purified on a 0.8% agarose gel with GeneClean (Bio101). The two purified PCR products were set up in individual kinase reactions as follows: 5μl DNA, 2μl ATP, 2μl 10X Protein Kinase buffer (New England Biolabs), 10μl dH₂O, and 1μl Protein Kinase. The reaction product was incubated a 37°C 2 hours. The resulting kinased products were purified through chloroform extraction and ethanol precipitated. The resultant products (3μl) were ligated together overnight (16°C) at their individual blunt ends with T4 ligase (New England Biolabs) in the following reaction mixture: 1μl 10X T4 ligase buffer, 2μl dH₂O, and 1μl T4 ligase. A second round of PCR using the primers CMV5'BssH (SEQ ID 2) and MA3'Tth (SEQ ID 4) amplified the final product to be cloned into the EIAV_{UK} clone. The reaction conditions were as stated above using 1μl of the ligation reaction. This final PCR product (50μl) was gel purified again on a 0.8% agarose gel. The purified PCR product was digested with the restriction enzymes BssHII and

- Tth111I in the following manner: 17µl PCR product, 2µl BssHII 10X buffer(NEB), and 2µl BssHII (NEB), incubated at 50°C for 2 hours, chloroform-extracted and ethanol precipitated. The digestion was completed as follows: 16µl DNA (BssHII digested), 2µl 10X reaction buffer
- 5 #4 (NEB), 2µl Tth111I, incubated at 65°C for 3 hours. The ElAV_{UK} clone (500ng) was partially digested with MluI (New England Biolabs). This was conducted through incubation at 37°C for 5 minutes in the following reaction mixture: 1µl 10X # reaction buffer, 1µl of restriction enzyme, 2µl of dH₂O and immediate submersion on ice followed by gel purification.
- 10 The appropriate size band was then completely digested with Tth111I in a reaction mixture consisting of 1µl 10X # 4 reaction buffer (NEB), 1µl of restriction enzyme and 2µl of dH₂O. The resulting fragment was gel purified on a 0.8% agarose gel. The promoter fragment (3µl) was ligated into the ElAV_{UK} clone (3µl) with T4 ligase in a mixture of 1µl 10X T4 ligase
- 15 buffer, 2µl dH₂O, and 1µl T4 ligase. The resulting ligation product (4µl) was transformed into competent DH5α bacterial cells (100µl). The transformation procedure consisted of: incubation on ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900µl SOC broth (a media supplement containing 20% bacto-tryptone, 5% bacto-yeast, 0.5% NaCl, 2.5mM KCl, 10 mM magnesium chloride and 20 mM glucose), incubation at 37°C for 1 hour, and 200µl
- 20 plated on LBamp plates. Clones were sequenced to verify correct promoter arrangement as schematically represented in Figure 3b

- The PCR, ligation, PCR method of cloning was used to delete the
- 25 Capsid Antigen (CA) sequence. Primers gag441 (SEQ ID No. 5) and MAT (SEQ ID No. 6) were used to amplify a 398 bp region of the molecularly-modified ElAV designated as CMVElAV_{UK} genome upstream of the CA open reading frame. PCR conditions were set up as follows in PGC Scientific thin-walled 0.5 ml PCR tubes: 40.6µl dH₂O, 5µl cloned Pfu DNA
- 30 Polymerase 10X reaction buffer, 0.8µl 25mM dNTP mixture, 2.5µl each primer (100ng/µl), 1µl template DNA (10ng/µl) 2.0µl cloned Pfu DNA

Polymerase (2.5 U/ μ l-Stratagene). Amplification was performed in a Hybaid thermocycler. Primers p9f5' (SEQ ID No. 7) and p9f3' (SEQ ID No. 8) were used to amplify a 357bp region of the CMVEIAV_{UK} genome downstream of the CA encoding region in a similar reaction mixture.

- 5 These two PCR products (50 μ l) were gel purified on a 0.8% agarose gel with GeneClean (Bio 101). The two purified PCR products (3 μ l) were ligated together overnight (16°C) with T4 ligase (New England Biolabs) in the following reaction mixture: 1 μ l 10X T4 ligase buffer, 2 μ l dH₂O, and 1 μ l T4 ligase. A final round of PCR was performed using the gag441 primer
- 10 (SEQ ID 5) and p9f3' primer (SEQ ID 8). The ligated sequence, when in the correct orientation would yield a PCR product of approximately 755bp. This deletes the CA open reading frame from base pairs 846-1550 (EIAV base pair correlation, not plasmid). The PCR product was gel purified on a 0.8% agarose gel with GeneClean. The purified fragment was digested
- 15 with Tth111I and BsrGI in the following manner: 15 μ l PCR product, 2 μ l BSA, 2 μ l 10X buffer #2 (NEB), and 2 μ l BsrGI (NEB), incubated at 37°C for 3 hours, chloroform extracted and ethanol precipitated. The digestion was completed as follows: 16 μ l DNA(BsrGI digested), 2 μ l 10X reaction buffer #4 (NEB), 2 μ l Tth111I, incubated at 65°C for 3 hours, and gel purified in
- 20 the same manner previously mentioned. The CMVEIAV_{UK} clone was digested with the same restriction enzymes and gel purified in a similar format. The two fragments (3 μ l each) were ligated together with T4 ligase in a mixture of 1 μ l 10X T4 ligase buffer, 2 μ l dH₂O, and 1 μ l T4 ligase, and transformed into competent DH5 α bacterial cells (100 μ l). The
- 25 transformation procedure consisted of: incubation on ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900 μ l SOC broth, incubation at 37°C for 1 hour, and 200 μ l plated on LBamp plates. Individual clones were screened for insert. Clones were sequenced to verify that the CA region had indeed been
- 30 deleted as schematically diagrammed in Figure 3c. The symbol Δ identifies the deletion.

The original proviral DNA carried an ampicillin resistance marker (Amp^r). Because this would not be the ideal marker for a vaccine used in mammals, it was replaced with a Kanamycin resistant marker (Kan^r) using the following procedure. The proviral DNA was subcloned into a

5 kanamycin-resistant vector designated as pLG339/SPORT (Cunningham et al. Gene, 124: 93-98, 1993). The vector was digested with the restriction enzymes MluI and EcoRI (New England Biolabs). The proviral clones were also digested fully with EcoRI and partially digested with MluI. The plasmids (500ng) were each partially digested individually through

10 incubation at 37°C for 5 minutes in the following reaction mixture: 2µl 10X # 1 reaction buffer, 1µl of restriction enzyme (MluI), 12µl of dH₂O and immediate submersion on ice followed by gel purification. The appropriate size band was then completely digested with EcoRI in a reaction mixture consisting of 1µl 10X #2 reaction buffer, 1µl of restriction enzyme and 2µl

15 of dH₂O. The desired fragments were gel purified on a 0.8% agarose gel with GeneClean. The proviral DNA (4µl) and vector (2µl) were ligated together overnight (16°C) with T4 ligase (New England Biolabs) in the following reaction mixture: 1µl 10X T4 ligase buffer, 2µl dH₂O, and 1µl T4 ligase. The ligation product (4µl) was transformed into competent DH5α

20 bacterial cells (100µl). The transformation procedure consisted of: incubation on ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900µl SOC broth, incubation at 37°C for 1 hour, and 200µl plated on LBKan plates. Individual clones were screened for insert into the proper MluI site. Figure 3d shows a

25 schematic representation of this construct demonstrating the Amp resistance marker being replaced by the Kan resistance marker.

A neomycin resistance marker (Neo^r) was added in order to allow selection of clones in eukaryotic cells. The neomycin resistance marker was excised from the commercial vector pRC/CMV (InVitrogen) using the

30 restriction enzymes EcoRI and XhoI (New England Biolabs). The area excised from the pRC/CMV encompassed the entire neomycin open

reading frame as well as the SV40 promoter, origin of replication, and SV40 poly A recognition sequence. The digestion was executed at 37°C in a reaction mixture which consisted of 500ng pRC/CMV plasmid DNA, 2µl 10X #2 reaction buffer, 2µl BSA, 2µl dH₂O, and 1µl each of the restriction enzymes. The resulting kanamycin-resistant proviral clone was digested with the restriction enzymes EcoRI and Sall (GIBCO BRL). Sall digested ends can ligate into XhoI digested ends. The digestion was carried out in the following reaction mixture: 1µl proviral DNA, 2µl 10X REACT 6 buffer, 2µl BSA, 2µl H₂O and 1µl each restriction enzyme. The digested neomycin fragment and proviral clone were gel purified on a 0.8% agarose gel with GeneClean, and ligated together at 16°C overnight with T4 ligase in the following reaction mixture: 4µl purified proviral DNA, 3µl purified neomycin insert DNA, 1.5µl 10X T4 ligase buffer, 5.5µl dH₂O and 1µl T4 ligase. The ligated DNA (6µl) was transformed into competent DH5α bacterial cells (100µl). The transformation procedure consisted of: incubation on ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900µl SOC broth, incubation at 37°C for 1 hour, and 200µl plated on LBKan plates. Individual clones were screened for insert. A schematic representation of the p26 deleted Proviral Clone pCMV.ΔCA.neo is shown in Figure 3e with a circular map shown in Figure 4.

EXAMPLE 2

Construction of an EIAV wherein a gene from a non-EIAV organism is inserted into the deleted p26 region (designated as pCMV.Vis2.neo): In order to substitute a foreign gene into the Capsid Antigen region (CA) of the gag gene and perhaps, to produce a replicating Proviral Clone with a p26 deletion, it was decided to insert the p30 gene from a Visna virus, a lentivirus (non-EIAV organism) which does not produce a positive response on the Coggins Test. If the p30 could be adapted to replace the

mechanism for p26 of the EIAV, then a replicating proviral clone could be produced.

As in EXAMPLE 1, the backbone for the construction of the Proviral Clone with the p30 of Visna inserted into the deleted p26 region was

5 EIAV_{UK} (Cook et al., *ibid*). A schematic diagram of this starting construct is shown in Figure 5a.

The procedure for preparation of this EIAV construct was as follows: The CMV promoter was inserted into the 5' LTR region of EIAV_{UK} through a process of PCR, ligation, PCR cloning as referenced previously.

10 Primers CMV3'Blunt (SEQ ID No.1) and 5'CMVBssH (SEQ ID No.2) were used to amplify the CMV promoter from the plasmid pRC/CMV (Invitrogen). PCR conditions were set up as follows in PGC thin-walled 0.5ml PCR tubes: 40.6µl dH₂O, 5µl cloned Pfu DNA Polymerase 10X reaction buffer, 0.8µl 25mM dNTP mixture, 2.5µl each primer (100ng/µl),
15 1µl template DNA (10ng/µl) 2.0µl cloned Pfu DNA Polymerase (2.5U/µl-Stratagene). Amplification was performed in a Hybaid thermocycler and consisted of 30 cycles of: 94°C-20 seconds, 60°C-20 seconds, 72°C-1 minute. Primers LTRBlunt5' (SEQ ID No. 3) and MA3'Tth (SEQ ID NO. 4) were used to amplify a region of the EIAV_{UK} clone encompassing the
20 portion of the genome including partial R region through the matrix open reading frame in similar reaction conditions. The PCR products (50µl) were gel purified on a 0.8% agarose gel with GeneClean (Bio 101). The two purified PCR products were set up in individual kinase reactions as follows: 5µl DNA, 2µl ATP, 2µl 10X Protein Kinase buffer (New England
25 Biolabs), 10µl dH₂O, and 1µl Protein Kinase. The reaction was incubated at 37°C 2 hours. The kinased products were purified through chloroform extraction and ethanol precipitated. The resultant products (3µl) were ligated together overnight (16°C) at their individual blunt ends with T4 ligase (New England Biolabs) in the following reaction mixture: 1µl 10X T4
30 ligase buffer, 2µl dH₂O, and 1µl T4 ligase. A second round of PCR using the primers CMV5'BssH (SEQ ID No. 2) and MA3'Tth (SEQ ID No. 4)

amplified the final product to be cloned into the EIAV_{UK} clone. The reaction conditions were as stated above using 1µl of the ligation reaction.

- This final PCR product (50µl) was gel purified again on a 0.8% agarose gel. The purified PCR product was digested with the restriction enzymes
- 5 BssHII and Tth111I in the following manner: 17µl PCR product, 2µl BssHII 10X buffer(NEB), and 2µl BssHII (NEB), incubated at 50°C for 2 hours, chloroform extracted and ethanol precipitated. The digestion was completed as follows: 16µl DNA (BssHII digested), 2µl 10X reaction buffer #4 (NEB), 2µl Tth111I, incubated at 65°C for 3 hours. The EIAV_{UK} clone
- 10 (500ng) was partially digested with MluI (New England Biolabs). This was conducted through incubation at 37°C for 5 minutes in the following reaction mixture: 1µl 10X # reaction buffer, 1µl of restriction enzyme, 2µl of dH₂O and immediate submersion on ice followed by gel purification. The appropriate size band was then completely digested with Tth111I in a
- 15 reaction mixture consisting of 1µl 10X # reaction buffer, 1µl of restriction enzyme and 2µl of dH₂O. The fragment was gel purified on a 0.8% agarose gel. The promoter (3µl) was ligated into the EIAV_{UK} clone (3µl) with T4 ligase in a mixture of 1µl 10X T4 ligase buffer, 2µl dH₂O, and 1µl T4 ligase. The ligation product (4µl) was transformed into competent
- 20 DH5α bacterial cells (100µl). The transformation procedure consisted of: incubation on ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900µl SOC broth, incubation at 37°C for 1 hour, and 200µl plated on LBamp plates. Clones were sequenced to verify correct promoter arrangement. Figure 5b is a
- 25 schematic representation of the EIAV_{UK} clone with the CMV promoter insert (CMVEIAV_{UK}).

- The source of the Visna p30 capsid sequence was the pVisna clone puc9-4.9V2 (Braun, MJ et al, Journal of Virology, 61(12): 4046-4054, 1987). The Visna p30 (7µl containing 1µg) was excised out of the
- 30 clone using the restriction enzymes Apal and Tth111I in the following reaction: 4µl dH₂O, 1.5µl BSA, 1.5µl 10X #4 reaction buffer (NEB), .5µl

Apal and Tth111I (NEB), incubated at 65°C for 2 hours; .5µl more of Apal added to the reaction mixture and incubated at room temperature (25°C) overnight. The desired fragment was gel purified in a 0.8% agarose gel with GeneClean. The CMVEIAV_{UK} clone (5µl containing 1µg) was
5 digested with BlnI (NEB enzyme for Bpu1102I) and Tth111I (NEB) in the following reaction mixture: 1.5µl 10X buffer #4 (NEB), and 1µl BsrGI (NEB), 7.5µl dH₂O, incubated at 37°C for 3 hours, chloroform extracted and ethanol precipitated. The digestion was completed as follows: 15µl
10 DNA(BlnI digested), 2µl 10X reaction buffer #4 (NEB), 1µl Tth111I, 2µl dH₂O, incubated at 65°C for 3 hours. The digested proviral DNA was gel purified on a 0.8% agarose gel with GeneClean. The two fragments were ligated with T4 ligase in the following mixture: DNA fragments (3µl each) were ligated together with T4 ligase in a mixture of 1µl 10X T4 ligase buffer, 2µl dH₂O, and 1µl T4 ligase. The ligation product (4µl) was
15 transformed into competent DH5α bacterial cells (100µl). The transformation procedure consisted of: incubation on ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900µl SOC broth, incubation at 37°C for 1 hour, and 200µl plated on LBamp plates. Individual clones were screened for insert and
20 sequenced using dideoxy sequencing and an ABI automatic sequencer to verify the entire visna p30 open reading frame was inserted in the proviral clone correctly and in frame. Figure 5c shows a schematic of the CMVEIAV_{UK}.vis2.

The proviral DNA was subcloned into a kanamycin-resistant vector
25 designated as pLG339/SPORT (Cunningham et al. Gene, 124: 93-98, 1993), incorporated herein by reference. The vector was digested partially with MluI and fully with EcoRI (New England Biolabs). The proviral clones were also digested fully with EcoRI and partially digested with MluI. The plasmids (500ng) were each partially digested individually through
30 incubation at 37°C for 5 minutes in the following reaction mixture: 2µl 10X #2 reaction buffer, 1µl of restriction enzyme, 12µl of dH₂O and immediate

- submersion on ice followed by gel purification. The appropriate size band was then completely digested with EcoRI in a reaction mixture consisting of 1µl 10X #2 reaction buffer, 1µl of restriction enzyme and 2µl of dH₂O. The desired fragments were gel purified on a 0.8% agarose gel with
- 5 GeneClean. The proviral DNA (4µl) and vector (2l) were ligated together overnight (16°C) with T4 ligase (New England Biolabs) in the following reaction mixture: 1µl 10X T4 ligase buffer, 2µl dH₂O, and 1µl T4 ligase. The ligation product (4µl) was transformed into competent DH5α bacterial cells (100µl). The transformation procedure consisted of: incubation on
- 10 ice for 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900µl SOC broth, incubation at 37°C for 1 hour, and 200µl plated on LBKan plates. Individual clones were screened for insert into the proper MluI site. Figure 5d shows a schematic of the proviral clone containing the kanamycin-resistance marker.
- 15 In order to make the EIAV proviral construct more commercially-acceptable, the kanamycin resistance marker was replaced with a neomycin resistance marker. The neomycin resistance marker was excised from the commercial vector pRC/CMV (InVitrogen) using the restriction enzymes EcoRI and XhoI. This encompassed the entire
- 20 neomycin open reading frame as well as the SV40 promoter (SEQ ID No. 9), origin of replication (SEQ ID. No. 10), and SV40 poly A recognition sequence (SEQ ID. No. 11). The digestion was executed at 37°C in a reaction mixture that consisted of 500ng pRC/CMV plasmid DNA, 2µl 10X #2 reaction buffer, 2µl BSA, 2µl dH₂O, and 1µl each of the restriction
- 25 enzymes. The new kanamycin-resistant proviral clone was digested with the restriction enzymes EcoRI and Sall (GIBCO BRL). Sall digested ends can ligate into XhoI digested ends. The digestion was carried out in the following reaction mixture: 1µg proviral DNA, 2µl 10X REACT 6 buffer, 2µl BSA, 2µl H₂O and 1µl each restriction enzyme. The digested neomycin
- 30 fragment and proviral clone were gel purified on a 0.8% agarose gel with GeneClean, and ligated together at 16°C overnight with T4 ligase in the

following reaction mixture: 4 μ l purified proviral DNA, 3 μ l purified neomycin insert DNA, 1.5 μ l 10X T4 ligase buffer, 5.5 μ l dH₂O and 1 μ l T4 ligase. The ligated DNA (6 μ l) was transformed into competent DH5 α bacterial cells (100 μ l). The transformation procedure consisted of: incubation on ice for 5 30 minutes, heat shock at 42°C for 45 seconds, incubation on ice for 2 minutes, addition of 900 μ l SOC broth, incubation at 37°C for 1 hour, and 200 μ l plated on LBKan plates. Individual clones were screened for insert. Figure 5e shows a schematic drawing of the final pCMVEIAV_{UK}-Vis2.neo proviral construct (hereinafter designated pCMV.Vis2.neo) and Figure 6 10 shows the final circular map of this construct.

The pCMV.Vis2.neo proviral construct was tested for its ability to replicate *in vitro* by using the standard replication assay as described in EXAMPLE 1. As with the Proviral Clone pCMV. Δ CA.neo, this pCMV.Vis2.neo proviral construct did not replicate *in vitro* and would not 15 be expected to replicate *in vivo*. It was therefore decided to develop a transfected cell line (persistently-infected cell line).

EXAMPLE 3

Transfection & Selection of Cell Lines: Transfection of an Equine 20 Dermal Cell Line

The p26-deleted Proviral Clone pCMV. Δ CA.neo and proviral construct pCMV.Vis2.neo were used to evaluate their ability to transfect cells in a manner similar to the wild-type EIAV_{UK}. The procedure used was as follows.

25 One microgram of proviral clone or proviral construct DNA was used to transfect an Equine Dermal (ED) cell line (ATCC CRL 6288). The ED cell line was grown in 6 well tissue culture plates seeded with between 2 and 4 x 10⁵ ED cells per well in 2 mL of the complete growth Minimum Essential Media with Earles salts (EMEM) plus 10% fetal calf serum, 100 30 units/mL of penicillin, 100 μ g/mL of streptomycin (Gibco BRL 15140-122) and 2 mm L-glutamine (Gibco BRL 25030-081). The plates were

incubated at 37° C in a CO₂ incubator approximately 16 to 24 hours until the cells are between 50 and 80% confluent. For each transfection, 1 µg of DNA was diluted into 100 µL of OPTI-MEM I Reduced Serum Medium (Gibco BRL 18324-012) and 10 µL of Lipofectamine reagent (Gibco BRL 18324-012) was added to 100 µL of OPTI-MEM I Reduced Serum Medium (OPTI-MEM RSM). The two solutions were mixed gently and incubated at room temperature for 30 minutes to allow the DNA-liposome complexes to form. During this time, the ED cell cultures were rinsed once with 2 mL of OPTIMEM I RSM (GIBCO-BRL). For each transfection, 0.8 mL of OPTI-MEM I RSM was added to the tube containing the DNA-liposome complexes, the tube was mixed gently and the contents were overlaid onto the rinsed cells. No antibiotics were added during transfection. The DNA-liposome/tissue cultures were incubated for 5 hours at 37°C in a CO₂ incubator. Following incubation, 1 mL of complete growth MEM containing twice the normal concentration of serum was added to the cell culture without removing the transfection mixture. Twenty four hours following the start of transfection the medium was replaced with fresh complete growth medium (EMEM). Starting at 48 to 72 hours post transfection, aliquots of the tissue culture supernatants were taken at periodic intervals and analyzed by using a standard reverse transcriptase (RT) assay as a measure of virus production. Supernatants resulting in RT activity were titrated in an infectivity assay based on cell-ELISA readings as described by Lichtenstein et al, 1995. Neither the Proviral Clone pCMV.ΔCA.neo nor the proviral construct pCMV.Vis2.neo replicated in tissue culture. The RT levels were less than or equal to those of the negative control in tissue culture cells normally capable of being infected with EIAV, that were exposed to the culture medium from the transfected cells. Therefore, it was determined that the deletion of p26 produced a defective virus particle, unable to replicate *in vitro* or *in vivo*. In order to obtain particles for large-scale vaccine production, it was decided to produce a

persistently-infected cell line with the Proviral Clone pCMV.ΔCA.neo and proviral construct pCMV.Vis2.neo.

Transfection of COS cells

- 5 Virus particles were produced using Proviral Clone pCMV.ΔCA.neo and the proviral construct pCMV.Vis2.neo transfected in the monkey cell line COS-1 (ATCC_CRL 1650). Cells were plated at approximately 50% confluency into 60mm plates (Falcon) 24 hours prior to transfection. Approximately 1μg of proviral clone DNA (pCMV.ΔCA.neo or
- 10 pCMV.Vis2.neo) was transfected into the cells using DEAE Dextran methodology. Briefly, a 50mg/ml solution of DEAE dextran was diluted 1:50 (1mg/ml final concentration) in Tris-buffered saline (TBS) with DNA and added to the cells in serum-free media (DMEM). The DNA solution was incubated on the cells for 1 hour at 37°C in the presence of 5% CO₂
- 15 with rocking every 15 minutes. Regular growth medium was replaced at this point. Forty-eight hours post-transfection the supernatants were assayed for RT activity. The RT activity was detected in cell-free supernatant samples using the micro reverse transcriptase assay (Lichtenstein et al., *ibid*). Protein content was detected using a Western
- 20 Blot Analysis procedure. For this procedure, virus particles were pelleted from 10mls of cell-free supernatant over a 20% glycerol cushion in an ultracentrifuge (Beckman SW41Ti rotor) at 50,000 x g for 45 min. Pellets were lysed in 100l of lysis solution containing 10mM NaCl, 1% Deoxycholic acid (DOC), 0.1% Sodium Dodecyl Sulfate (SDS), 25mM
- 25 Tris-HCl and 1% TritonX-100 and transferred to 1.5ml eppendorf tubes. After lysis, the samples were boiled in 20μl of 6X SDS gel loading buffer and loaded onto a 12% SDS-polyacrylamide gel. Gradient purified EIAV_{PV} (1μg) was also loaded onto the gel to serve as a marker for viral proteins. Electrophoresis was carried out at approximately 10mA overnight with
- 30 cooling. Proteins were transferred onto Millipore membranes using BioRad's protein transfer cell system in a buffer containing 25mM Tris,

192mM glycine, 20% methanol and 0.05% SDS. Transfer was completed after 3 hours at 400mA with cooling. EIAV proteins were detected using monoclonal antibodies. Prior to antibody incubation the blot was blocked in 5% blotto (5% drymilk, 5% FBS and 0.25% Tween-20 in 1X PBS) for 1
5 hour at room temperature. Mouse monoclonal α -gp90 and α -p26 were used together in 5% blotto for 1 hour at room temperature. Secondary antibody α -mouse 1gG conjugated with horse-radish-peroxidase (Sigma lot # 115H8995) was incubated at room temperature for one hour. The blot was washed for 3-5 minute periods in 1XPBS/0.025% Tween-20
10 between primary and secondary antibody incubations. A one minute incubation at room temperature of the chemi-illuminiscent substrate SuperSignal (Pierce lot #AE40027) followed the final wash after the secondary antibody incubation. Exposure of the blot to film demonstrated that both gp90 and p26 were detectable in the EIAV_{pv} positive control; but
15 only gp90 was detectable in the proviral clone pCMV. Δ CA.neo and the proviral construct pCMV.Vis2.neo. Production of the virus particles was observed through both RT activity and by Western Blot analysis.

Stable Transfections in CHO, C-33A & ED-MCS Cell Lines

20 Stable production of virus particles was attempted in three cell lines; a human cell line C-33A (ATCC HTB-31), a chinese hamster ovary cell, CHO (ATCC CRL-9618), and an equine cell line ED-MCS. Transfections were all done in duplicate. Cells were consistently maintained in an incubator at 37°C with 5%CO₂. Cell lines were seeded
25 onto 10mm plates manufactured by Sarstedt and Falcon 24 hours prior to transfection at the following densities: CHO & C-33A 1X 10⁶ cells/plate, ED-MCS 3.5 X 10⁵ cells/plate. Proviral clones, pCMV.Vis2.neo and pCMV. Δ CA.neo (20 μ g/plate) were transfected into the cells using 55 μ l of the reagent GenePORTER™ (Gene Therapy Systems) in serum-free
30 DMEM (Gibco). Manufacturers' instructions were followed. Twenty-four hours post-transfection media was changed from transfection media to

selection media (DMEM) which contained 800µg/ml G-418 (Geneticin, Gibco BRL) and 10% FBS (Hyclone). A plate that was not transfected was carried as a control for selection in the same media. Once the control plate had no viable cells present and the selected plates displayed colony formation; cells were passed into T75 flasks (Falcon) as bulk cultures. The level of G-418 in the ED-MCS cells was increased to 1000µg/ml due to rapid growth. Supernatants were analyzed throughout the selection period for RT activity and at individual points assayed for protein content through Western blot analysis. RT activity initially indicated highest production in the human and mouse cell lines. The equine dermal cell line proved to develop the most stable construct during long-term production, producing continuously the highest levels out to post-selection day 150. This experiment proved that tissue culture cells can be transfected by the p26-deleted clone as well as by the chimera wherein a foreign gene from a Visna virus (p30) was inserted into the p26 region. Reverse transcriptase activity from these transfected cells reached levels as high as 10,000 CPM/10µl of tissue culture fluid. This is equivalent to RT activity produced by wild-type EIAV when transfected into tissue culture. Western Blot analysis was conducted as described previously except that a second western blot was done in the same format as before, re-probing the membrane with goat α-Visna p30 to detect the Visna chimera proteins. Secondary antibody was α-goat IgG whole molecule-HRP (Sigma lot# 117H4831). The Visna p30 protein was detected in the Visna chimeric proviral construct pCMV.Vis2.neo (See Figure 10b).

Western Blot Analysis

Virus particles were pelleted from 10mls of cell-free supernatant over a 20% glycerol cushion in the ultracentrifuge SW41Ti rotor (Beckman). Pellets were lysed in 100µl of lysis solution containing 10mM sodium chloride (NaCl), 1% DOC, 0.1% Sodium Dodecyl Sulafte (SDS), 25mM Tris-HCl and 1% TritonX-100 and transferred to 1.5ml eppendorf tubes. After lysis, the samples were boiled in 20µl of 6X SDS buffer gel

loading buffer and loaded onto a 12% SDS-polyacrylamide gel. One microgram of gradient purified pony virus EIAV_{PV} was also loaded onto the gel to serve as a marker for viral proteins. Electrophoresis was carried out at approximately 10mA overnight with cooling. Proteins were transferred
5 onto Millipore membranes using BioRad's protein transfer cell system in a buffer containing 25mM Tris, 192mM glycine, 20% methanol and 0.05% SDS. Transfer was completed after 3 hours at 400mA with cooling. EIAV proteins were detected using monoclonal antibodies. Prior to antibody incubation the blot was blocked in 5% blotto (5% drymilk, 5% FBS and
10 0.25% Tween-20 in 1X PBS) for 1 hour at room temperature. Mouse monoclonal α -gp90 and α -p26 were used together in 5% blotto for 1 hour at room temperature. Secondary antibody α -mouse IgG conjugated with horse-radish-peroxidase (Sigma lot # 115H8995) was incubated at room temperature for one hour. The blot was washed for 3-5 minute periods in
15 1XPBS/0.025% Tween-20 between primary and secondary antibody incubations. A one minute incubation at room temperature of the chemiluminescent substrate SuperSignal (Pierce lot #AE40027) followed the final wash after the secondary antibody incubation. Exposure of the blot to film demonstrated that both gp90 and p26 were detectable in the PV
20 positive control; but only gp90 was detectable in the proviral clones (pCMV.Vis2.neo and pCMV.CA.neo), see FIGURE 10a. The membranes were stripped through incubation in Glycine-Cl pH 2.3 buffer (0.05M glycine 0.15M NaCl) for 45 minutes. The membranes were washed in the same wash buffer for 7-5 minute periods and blocked in 5% blotto for 2
25 hours. The second western was done in the same format as before, re-probing the membrane with goat α -Visna p30 to detect the Visna chimera proteins. Secondary antibody was α -goat IgG whole molecule-HRP (Sigma lot# 117H4831). The Visna p30 protein was detected in the Visna chimeric proviral constructs (pCMV.Vis2.neo) see FIGURE 10b.
30 The presence of gp90 indicates that these p26-deleted constructs produce the protective antigen. Not only do they lack the ability to

produce p26 antibodies in animals but they also cause the animals vaccinated with them to produce antibodies to p30. The presence of p30 in an equine will indicate that the horse has been vaccinated. An assay to detect the presence of this p30 antibody can be developed in order to
5 differentiate horses that are vaccinated with the vaccines of this invention from horses that have not been vaccinated or horses that have been infected with wild-type EIAV. Additionally, a diagnostic that detects all or part of the p30 gene sequence or the p30 protein can be used similarly as a diagnostic tool.

10

EXAMPLE 4 Subcloning - Single Cell Cloning of the Stable Transfection

Stably-selected Visna (pCMV.Vis2.neo) transfected ED-MCS cells which had been frozen back at day 40 of selection were thawed at 37°C and seeded into a T75 flask in normal growth medium (no G-418). Cells
15 were grown at 37°C with 5% CO₂ in G-418-negative medium for 48-hours prior to plating for cloning. Cells were trypsonized from the T75 flasks, counted, and plated onto 100mm Falcon plates at densities of approximately 100 cells per plate. The cells were selected in medium containing 800µg/ml G-418. Media was changed approximately every
20 four days and cells were grown in the plates until visible colonies had formed. Independent colonies were trypsonized from the plates separately through the use of cloning cylinders and seeded into separate cells of Falcon 24-well plates. These were also selected in media containing 800µg/ml G-418. Approximately 7 days post-transfer the cell
25 supernatants were assayed for RT activity. The was conducted as follows:

For each 10µl sample of cell-free supernatant to be assayed the following is added:

30	³ H-TTP (40Ci/mmol)	1.5 µl
	-dried in speedvac and volume made up with the volume of water below	
	100mM EGTA	5.0 µl
	10X Salts	5.0 µl

	(2M Tris-Cl pH 8.0, 2M KCl, 1M MgCl ₂ , 1M DTT, 20% NP-40, DI Water)	
	poly(rA).p(dT) ₁₂₋₁₃	2.0 μ l
	(5 units/ml ~ .25mg/ml)	
5	millipore water	<u>38.0 μl</u>
		50.0 μ l

The mixture of supernatant (sample) and reaction mixture are mixed together and incubated at 37°C for 1.5hr-2.0hr. The total volume is (~60 μ l)

10 pipetted onto DEAE coated filter paper and allowed to dry completely. The filters are then washed 3X for 15 minute each in 1X SSC and again allowed to dry completely. The filters are then immersed in scintillation fluid and the incorporated activity measured. As a result of using this RT assay, the 12 "subclones" with the highest RT activity were trypsonized

15 and passaged into 6-well plates (Falcon), still selecting in 800 μ g/ml G-418. Supernatants were analyzed for RT activity after 4 days of selection in the 6-well plates. The 8 subclones with the highest RT activity were trypsonized and passaged into T75 flasks (Falcon) still selecting in 800 μ g/ml G-418. Supernatants were analyzed for RT activity after 7 days

20 of selection in the flasks. The amount of G-418 was reduced at this passage point to 600 μ g/ml. Selection was carried out for 4 more days, RT activity analyzed, and the level of G-418 lowered again to 400 μ g/ml. After 7 days of selection another RT assay was performed on the 8 subclones to monitor selection. Following 7 more days of selection, another RT

25 assay was performed. The 4 highest producing cell lines were passaged again, lowering the level of G-418 to 200 μ g/ml (the other 4 were frozen back). The highest-producing subclone, F-1V2.23, was producing a high level of RT activity (between 4000 and 50,000 CPM per 10 μ l of tissues culture fluid as shown in Figure 11. This result indicates that the

30 constructs of this invention can be produced *in vitro* in enough quantity to produce commercial vaccines.

The fact that the constructs of this invention were able to demonstrate the presence of the gp90 protective component and

displayed significant EIAV RT activity provides assurance that a vaccine prepared according to this invention would be useful in protecting animals from disease and/or infection from lentiviruses, particularly EIAV.

- 5 Additionally, it has been demonstrated that said vaccine lacks the ability to stimulate antibodies to p26 and that it would produce antibodies to p30 so that vaccinated animals can be differentiated from infected or non-exposed animals. Most importantly, the insertion of a foreign gene into the EIAV genome such that said foreign gene is expressed indicates the usefulness of this lentivirus as a vector or as a virus construct into which
- 10 multiple genes could be inserted. Such a multiple gene insertion could provide for an EIAV vaccine that protects from multiple diseases.

Although the invention has been described in detail in the foregoing, for the purpose of illustration it is to be understood that such detail is solely for that purpose and that variations can be made therein by those skilled in the art without departing from the spirit and scope of the
5 invention except as it may be limited by the claim.

WHAT IS CLAIMED:

1. A vaccine that produces protection from disease and/or infection caused by a lentivirus comprising a lentivirus that lacks the ability to replicate *in vivo*.
- 5 2. A vaccine that produces protection from disease and/or infection caused by a lentivirus comprising a lentivirus that lacks the ability to express a Capsid Antigen
3. The vaccine according to Claim 2 wherein the lack of ability to express Capsid Antigen results from one or more deletions in a gene region selected from the group consisting of a portion of the *gag* gene, all
10 of the *gag* gene and a gene regulating expression of the *gag* gene or an insertion of a stop codon in a gene affecting the expression of the *gag* gene.
4. The vaccine according to Claim 1 wherein the lentivirus lacks
15 the ability to replicate *in vitro*.
5. The vaccine according to Claim 2 wherein the lentivirus lacks the ability to replicate *in vitro*.
6. The vaccine according to Claim 4 wherein said gene-deleted lentivirus is produced in large quantities by a cell line transfected with the
20 gene-deleted lentivirus.
7. The vaccine according to Claim 5 wherein said gene-deleted lentivirus is produced in large quantities by a cell line transfected with the gene-deleted lentivirus.
8. The vaccine according to Claim 1 which, safely and
25 effectively immunizes mammals against disease and/or infection caused by a lentivirus and further allows for differentiation between vaccinated, non-vaccinated and wild-type exposed mammals.
9. The vaccine according to Claim 2 which, safely and
effectively immunizes mammals against disease and/or infection caused
30 by a lentivirus and further allows for differentiation between vaccinated, non-vaccinated and wild-type exposed mammals.

10. The vaccine according to Claim 1 wherein said lentivirus is selected from the group consisting of equine infectious anemia virus (EIAV), human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and simian
5 immunodeficiency virus (SIV).

11. The vaccine according to Claim 2 wherein said lentivirus is selected from the group consisting of equine infectious anemia virus (EIAV), human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and simian
10 immunodeficiency virus (SIV).

12. The vaccine according to Claim 11 wherein the lentivirus EIAV lacks the ability to express p26 antigen and is safe and effective.

13. The vaccine according to Claim 12 wherein the lack of the ability to express p26 antigen results from a non-functional gag gene.

15 14. The vaccine according to Claim 13 wherein the non-functional *gag* gene results from a deletion in the gag gene.

15. The vaccine according to Claim 13 wherein the deletion in the gag gene results from one or more deletions in a gene region selected from the group consisting of a portion of the gag gene, all of the gag gene
20 and a gene regulating expression of the gag gene or an insertion of a stop codon in a gene affecting the expression of the gag gene.

16. The vaccine according to Claim 11 wherein the gene-deleted EIAV further lacks the ability to replicate *in vitro*.

17. A vaccine for effectively and safely immunizing equines from
25 EIA, said vaccine comprising a gene-deleted EIAV wherein said gene-deleted EIAV lacks the ability to express p26 and allows differentiation of vaccinated from wild type exposed equines.

18. The vaccine of Claim 17 further comprising an adjuvant.

19. The vaccine of Claim 17 wherein the EIAV is inactivated.

30 20. The vaccine of Claim 17 comprising an inactivated EIAV and an adjuvant

21. A method of immunizing mammals against disease produced by an EIAV comprising, administering to said mammals the vaccine of Claim 11.

5 22. An EIAV vaccine that allows equines to be safely vaccinated and protected from disease and/or infection without converting to a seropositive status on the Coggins Test or any other test which measures p26 antibodies.

23. A diagnostic to detect all or a portion of the gag gene of EIAV comprising a PCR probe for said gene.

10 24. A diagnostic to differentiate between a vaccinated and wild type exposed equine comprising the PCR probe of Claim 23.

25. A method of preparing a lentivirus vaccine comprising:

- 15
- 1) deleting all or a portion of a gag gene from the lentivirus;
 - 2) transfecting a tissue culture with the resulting gene-deleted lentivirus to produce a persistently transfected cell culture;
 - 3) growing the persistently transfected cell culture;
 - 4) harvesting the persistently-transfected cell culture;
 - 5) optionally inactivating the harvested cell culture; and
- optionally adjuvanting the harvested cell culture.

Figure 1 Schematic representation of ELA virus ELA V_{UK}





Figure 2 Circular Map of Infectious Clone ELAV_{UK}



Figure 3a Linear Schematic of the Molecular Clone EIAV_{UK}**Figure 3b** Linear Schematic of Molecular Clone EIAV_{UK} with the CMV Promoter**Figure 3c** Linear Schematic of Molecular Clone EIAV_{UK} with the CA gene deleted**Figure 3d** Linear Schematic of Molecular Clone EIAV_{UK} with the Amp Resistance Gene Replaced by the Kanamycin Resistance Gene**Figure 3e** Linear Schematic of the p26 Deleted Proviral Clone pCMV.ΔCA.neo

Figure 4 **pCMV.ΔCA.neo**








Figure 5a Linear Schematic Representation of EIAV_{UK}**Figure 5b** Linear Schematic Representation of the EIAV_{UK} clone with the CMV promoter insert (CMVEIAV_{UK})**Figure 5c** Linear Schematic Representation of the CMVEIAV_{UK-vis2}.**Figure 5d** Linear Schematic Representation of the Proviral Clone containing the Kanamycin Resistance Marker.**Figure 5e** Linear Schematic Representation of the final pCMV.Vis2.neo Proviral Construct

Figure 6 Circular map of the final pCMV.Vis2.neo Proviral Construct.




Figure 7 Nucleotide and Amino Acid Map of the Capsid Antigen
Gene/EIA Virus p26 Protein

10	20	30	40	50	60	70	
CCAATCATGATAGATGGGGCTGGAAACAGAAATTTTAGACCTCTAACACCTAGAGGATATACTACTTGGGTGAATACC							
P I M I D G A G N R N F R P L T P R G Y T T W V N T							
80	90	100	110	120	130	140	150
ATACAGACAAATGGTCTATTAAATGAAGCTAGTCAAACTTATTTGGGATATTATCAGTAGACTGTACTTCTGAAGAA							
I Q T N G L L N E A S Q N L F G I L S V D C T S E E							
160	170	180	190	200	210	220	230
ATGAATGCATTTTTGGATGTGGTACCTGGCCAGGCAGGACAAAAGCAGATAATTACTTGATGCAATTGATAAGATAGCA							
M N A F L D V V P G Q A G Q K Q I L L D A I D K I A							
240	250	260	270	280	290	300	310
GATGATTGGGATAATAGACATCCATTACCGAATGCTCCACTGGTGGCACCACCACAAGGGCCTATTTCCCATGACAGCA							
D D W D N R H P L P N A P L V A P P Q G P I P M T A							
320	330	340	350	360	370	380	390
AGGTTTATTAGAGGTTTAGGAGTACCTAGAGAAAGACAGATGGAGCCTGCTTTTGATCAGTTTAGGCAGACATATAGA							
R F I R G L G V P R E R Q M E P A F D Q F R Q T Y R							
400	410	420	430	440	450	460	
CAATGGATAATAGAAGCCATGTGAGAAGGCATCAAAGTGATGATTGGAAAACCTAAAGCTCAAAATATTAGGCAAGGA							
Q W I I E A M S E G I K V M I G K P K A Q N I R Q G							
470	480	490	500	510	520	530	540
GCTAAGGAACCTTACCCAGAATTTGTAGACAGACTATTATCCCAAATAAAAAGTGAGGGACATCCACAAGAGATTCA							
A K E P Y P E F V D R L L S Q I K S E G H P Q E I S							
550	560	570	580	590	600	610	620
AAATTCTTGACTGATACACTGACTATTTCAGAACGCAATGAGGAATGTAGAAATGCTATGAGACATTTAAGACCAGAG							
K F L T D T L T I Q N A N E E C R N A M R H L R P E							
630	640	650	660	670	680		
GATACATTAGAAGAGAAAATGTATGCTTGCAGAGACATTGGAACACAAAACAAAAGATGATGTT							
D T L E E K M Y A C R D I G T T K Q K M M L							

Figure 8 Nucleotide and Amino Acid Map of the CA gene/Visna Virus p30

10 20 30 40 50 60 70
CCTATTGTGAATTTGCAAGCAGGAGGGAGAAGTTGGAAGGCGGTAGAGTCAGTAGTCTTCCAGCAACTGCAAACAGTG
P I V N L Q A G G R S W K A V E S Y V F Q Q L Q T V

80 90 100 110 120 130 140 150
GCAATGCAGCATGGACTTGTGTCCGAGGATTTTGAGAGGCAATTGGCATATTATGCTACTACCTGGACTAGTAAAGAT
A M Q H G L V S E D F E R Q L A Y Y A T T W T S K D

160 170 180 190 200 210 220 230
ATATTAGAAGTATTGGCTATGATGCCTGGGAATAGAGCACAGAAGGAATTAATACAAGGAAAATTAAATGAAGAAGCA
I L E V L A M M P G N R A Q K E L I Q G K L N E E A

240 250 260 270 280 290 300 310
GAAAGGTGGGTAAGACAAAATCCACCCGGGCCGAATGTCTCACGGTGGATCAAATAATGGGAGTGGGACAAACCAAT
E R W V R Q N P P G P N V L T V D Q I M G V G Q T N

320 330 340 350 360 370 380 390
CAGCAGGCATCTCAAGCCAATATGGATCAGGCAAGACAGATATGCCTGCAGTGGGTAATAACAGCGTTAAGATCAGTG
Q Q A S Q A N M D Q A R Q I C L Q W V I T A L R S V

400 410 420 430 440 450 460
AGGCATATGTCACATAGACCAGGAAACCCCTATGTTAGTGAAGCAGAAGAATACTGAGAGTTATGAAGACTTCATAGCT
R H M S H R P G N P M L V K Q K N T E S Y E D F I A

470 480 490 500 510 520 530 540
CGCCTACTAGAGGCTATTGATGCGGAACCAGTGACGGACCCCTATAAAAACATATTTAAAGTAACATTGTTCATATACA
R L L E A I D A E P V T D P I K T Y L K V T L S Y T

550 560 570 580 590 600 610 620
AATGCTAGCACAGACTGTCAAAAGCAGATGGATAGGACATTGGGGACGAGGGTTCAACAAGCAACGGTAGAAGAAAAG
N A S T D C Q K Q M D R T L G T R V Q Q A T V E E K

630 640 650 660 670
ATGCAAGCATGTCGAGATGTGGGATCCGAAGGATTTAAGATGCAATTA
M Q A C R D V G S E G F K M Q L

PCT/US01/27600

BOTTOM= EIAV p26

PCT/US01/27600

PCT/US01/27600

Figure 9 Cont'd

390 400 410 420 430 440 450 460 470
AAGATCAGTGAGGCATA-TGTCACATAGACCAGGAAACCTATGTTAGTGA--AGCAGA---AGAATACTGAGAGTTATG-AAGACTTCATAGCTCG
.. ..
CATATAGACAATGGATAATAGAAGCCATGTCAGAAGGCATCAAAGTGATGATTGGAAAACCTAAGCTCAAAATATTAGGCAAGGAGCTAAGGAACC
390 400 410 420 430 440 450 460 470

480 490 500 510 520 530 540 550 560
CCTACTAGAGGCTATTGATGCGGAACCACTGACGGACCCCTATA-AAAACATATTAAAGTAACATTGTCATATACAAATGCTAGCACAGACTGT-C
.. ..
TTACCCAGAATTTGTAGACAGACTATTA-TCCCAATAAAAAGTGAGGGACATCCACAAGAGATTTCAAAATTCCTTGACTGATA-CACTGACTATTC
480 490 500 510 520 530 540 550 560 570

570 580 590 600 610 620 630 640 650
AAAA-GCAGATGGATAGGACATTGGGG--ACGAGG-GTTCAACA---AGCA-ACGCTAGAGAAAAGATGCAAGCATGTCGAGATGTGGGATCCGA
.. ..
AGAACGCAAAATGAGGAATGTAGAATGCTATGAGACATTTAAGACCAGAGGATACATTAGAAGAGAAAATGTATGCTTGCAGAGACATTGGAACTAC
580 590 600 610 620 630 640 650 660 670

660 670
AGGATTTAAGATGCAATTA
.. ..
AAAACAAAAGATGATGTT-
680

Figure 10a Western Blot of EIA Virus Constructs




Figure 10b Western Blot of EIA Virus Constructs



Anti-Goat α -Visna p30 Monoclonal Antibody

Figure 11 Reverse Transcriptase Activity of Subclones of Tissue Culture Cells Transfected with pCMV.Vis2.neo Proviral Construct



SEQUENCE LISTING

<110> MONTELARO, Ronald
CRAIGO, Jodi K.
ISSEL, Charles
PUFFER, Bridget
HENNESSY, Kristina J.
BROWN, Karen K.

<120> EIAV P26 DELETION VACCINE AND DIAGNOSTIC

<130> MONTELARO ET AL.

<140> 09/659,026

<141> 2000-09-09

<160> 11

<170> PatentIn Ver. 2.1

<210> 1

<211> 24

<212> DNA

<213> GIBCO

<400> 1

aatttcgata agccagttaa gcag

24

<210> 2

<211> 26

<212> DNA

<213> GIBCO

<400> 2

ctggcgcgcg atcgacgggc cagata

26

<210> 3

<211> 28

<212> DNA

<213> GIBCO

<400> 3

ggcctttcta ataaatataa ttctctac

28

<210> 4

<211> 27
<212> DNA
<213> GIBCO

<400> 4
aggcctctct tccttgtcct gacagcg

27

<210> 5
<211> 27
<212> DNA
<213> GIBCO

<400> 5
tggccagaac acaggaggac aggtaag

27

<210> 6
<211> 29
<212> DNA
<213> GIBCO

<400> 6
gatattcttc agagggtca gactgcttt

29

<210> 7
<211> 25
<212> DNA
<213> GIBCO

<400> 7
cagactggtc ttgcgggcc attta

25

<210> 8
<211> 23
<212> DNA
<213> GIBCO

<400> 8
catactctac ttgaccttc tcc

23

<210> 9
<211> 226
<212> DNA
<213> IN VITROGEN

<400> 9

ccaggcaggc acaagtatgc aaagcatgca tctcaattag tcagcaacca ggtgtggaaa 60
gtccccaggc tccccagcag gcagaagtat gcaaagcatg catctcaatt agtcagcaac 120
catagtcccg cccctaactc cgcccatccc gcccctaact ccgcccagtt ccgcccattc 180
tccgcccatt ggtgactaa ttttttttat ttatgcagag gccgag 226

<210> 10

<211> 86

<212> DNA

<213> IN VITROGEN

<400> 10

gactaatttt ttttatttat gcagaggccg aggccgcctc tgcctctgag ctattccaga 60
agtagtgacc aggtttttt ggaggc 86

<210> 11

<211> 131

<212> DNA

<213> IN VITROGEN

<400> 11

acttctttat tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa 60
ataaagcatt ttttctactg cattctagtt ctggtttgtc caaactcctc aatgtatctt 120
atcatgtctg t 131

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/020050 A3

(51) International Patent Classification⁷: A61K 39/21,
C12N 7/04, 15/49, C12Q 1/70, G01N 33/569

(74) Agent: BLACKSTONE, William; Intervet Inc., Patent
Department, Akzo Nobel, 405 State Street, Millsboro, DE
19966 (US).

(21) International Application Number: PCT/US01/27600

(22) International Filing Date:
6 September 2001 (06.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/659,026 9 September 2000 (09.09.2000) US

(71) Applicant (for all designated States except US): AKZO
NOBEL N.V. [NL/NL]; Velperweg 76, P.O. Box 186,
NL-6800 LS Arnhem (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MONTELARO,
Ronald, C. [US/US]; 127 Greenbriar Drive, Wexford, PA
15090 (US). CRAIGO, Jodi [US/US]; 12 Hillcrest Drive,
Pittsburgh, PA 15202 (US). ISSEL, Charles [US/US]; 725
Edgewater Drive, Lexington, KY 40502 (US). PUFFER,
Bridget [US/US]; 219 Strathmore Place, Corning, NY
14830 (US). HENNESSEY, Kristina, J. [US/US]; 5215
N.W. Bluff Drive, Parkville, MO 64152 (US). BROWN,
Karen, K. [US/US]; 5501 N.W. Foxhill Road, Parkville,
MO 64152 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— with international search report

(88) Date of publication of the international search report:
28 August 2003

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 13/2003 of 27 March 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: EIAV P26 DELETION VACCINE AND DIAGNOSTIC

(57) Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease with converting to a seropositive status on the Coggin's Test or any other test which measures p26, said p26 antigen being expressed in disease-producing wild-type EIAVs. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines. Finally, this invention encompasses a marker vaccine in which vaccinated equines can be distinguished from non-vaccinated equines by detection of a foreign gene in the vaccinated animals. A diagnostic test to detect this foreign gene or gene product is also described.

WO 02/020050 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/27600

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/21 C12N7/04 C12N15/49 C12Q1/70 G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 05292 A (ROVINSKI BENJAMIN ;CONNAUGHT LAB (CA); PERSSON ROY (CA); CAO SHI X) 22 February 1996 (1996-02-22)	1,4,6,8, 10
Y	examples 1-5	2,3,5,7, 9,11-21
X	TRONO D ET AL: "HIV-1 GAG MUTANTS CAN DOMINANTLY INTERFERE WITH THE REPLICATION OF THE WILD-TYPE VIRUS" CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 59, no. 1, 6 October 1989 (1989-10-06), pages 113-120, XP000068030 ISSN: 0092-8674	1-11,25
Y	page 114, column 2; figure 1; table 3 --/--	12-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

8 April 2003

Date of mailing of the international search report

16/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Brouns, 6

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/27600

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIM C H ET AL: "GENOMIC VARIATION AND SEGREGATION OF EQUINE INFECTIOUS ANEMIA VIRUS DURING ACUTE INFECTION" JOURNAL OF VIROLOGY, vol. 66, no. 6, 1992, pages 3879-3882, XP008014364 ISSN: 0022-538X figures 1,2	23,24
Y	ISSEL C J ET AL: "EFFICACY OF INACTIVATED WHOLE-VIRUS AND SUBUNIT VACCINES IN PREVENTING INFECTION AND DISEASE CAUSED BY EQUINE INFECTIOUS ANEMIA VIRUS" JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 6, 1 June 1992 (1992-06-01), pages 3398-3408, XP000654017 ISSN: 0022-538X page 3398, column 2 -page 3399, column 1	12-20
Y	WO 97 31119 A (RES INST FOR GENETIC AND HUMAN) 28 August 1997 (1997-08-28) claim 11; example 3	2,3,5,7, 9,11,21
Y	US 5 674 720 A (GORELICK ROBERT J ET AL) 7 October 1997 (1997-10-07) page 2; example 2	2,3,5,7, 9,11,21
A	LU J ET AL: "DIFFERENTIAL TEST ON SERUM ANTIBODY FROM EIA HORSES WITH THAT FROM ATTENUATED EIA VACCINE IMMUNIZED HORSES" SCIENTIA AGRICULTURA SINICA, vol. 22, no. 6, 1989, pages 69-75, XP001148407 ISSN: 0578-1752 abstract	1-25
P,A	WO 00 63387 A (CHEN GANG ;FAN XIUJUAN (CN); FENG YI (CN); JIA BIN (CN); SHAO YIMI) 26 October 2000 (2000-10-26) example 2	1-25
L	& EP 1 174 507 A (HARBIN VETERINARY RES INST CHI ;NAT CT FOR AIDS PREVENTION AND (CN) 23 January 2002 (2002-01-23) EP family member of WO0063387, for language purposes	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/27600

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 21 is directed to a prophylactic method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☒ Claims Nos.: 22
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 22

Present claim 22 relates to a vaccine defined by reference to a desirable characteristic or property, namely that it allows equines to be safely vaccinated and protected from disease and/or infection without converting to a seropositive status on the Coggins Test or any other test which measures p26 antibodies.

The claims cover all vaccines having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such vaccines, which are the subject-matter of other claims, in particular claims 12 and 17.

In the present case, claim 22 so lacks support, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the vaccine by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for claim 22.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/27600

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9605292	A	22-02-1996	US 5955342 A	21-09-1999
			AU 704309 B2	22-04-1999
			AU 3159995 A	07-03-1996
			CA 2197446 A1	22-02-1996
			WO 9605292 A1	22-02-1996
			EP 0778888 A1	18-06-1997
			JP 10503933 T	14-04-1998
			US 5866320 A	02-02-1999
			US 6518030 B1	11-02-2003
			US 6342228 B1	29-01-2002
			US 5889176 A	30-03-1999
			US 5879925 A	09-03-1999
			US 6025125 A	15-02-2000
WO 9731119	A	28-08-1997	AP 964 A	11-05-2001
			AU 726623 B2	16-11-2000
			AU 2136997 A	10-09-1997
			CA 2246359 A1	28-08-1997
			EA 2020 B1	24-12-2001
			EP 0882134 A1	09-12-1998
			JP 2000517290 T	26-12-2000
			NZ 331369 A	27-04-2001
			WO 9731119 A1	28-08-1997
US 5674720	A	07-10-1997	AT 162949 T	15-02-1998
			AU 636755 B2	06-05-1993
			AU 7740291 A	31-05-1991
			CA 2072125 A1	01-05-1991
			DE 69032028 D1	12-03-1998
			DE 69032028 T2	20-05-1998
			DK 500791 T3	06-04-1998
			EP 0500791 A1	02-09-1992
			ES 2111559 T3	16-03-1998
			GR 3026457 T3	30-06-1998
			JP 7016420 B	01-03-1995
			JP 4505163 T	10-09-1992
			WO 9106318 A1	16-05-1991
WO 0063387	A	26-10-2000	CN 1271015 A	25-10-2000
			AU 3955400 A	02-11-2000
			WO 0063387 A1	26-10-2000
			EP 1174507 A1	23-01-2002

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.